Shares of Merck & Co. Inc. slipped 4.81% to $87.87 Tuesday, on what proved to be an all-around favorable trading session for ...

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...